CFDA Proposes Sweeping Action On Approvals, Poor Quality Submissions
This article was originally published in PharmAsia News
From enforcing bioequivalence testing to punishing clinical data forgery, from requiring self-audits to forbidding simple formulation changes, the China FDA is proposing to strike hard against poor quality approval filings and meanwhile accelerate reviews for pediatric drugs and products submitted simultaneously with the US and EU.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.